INTERVIEW: Akers' IPO funds help lay foundations for progress
This article was originally published in Clinica
Executive Summary
2014 is looking like a transformational year for point-of-care testing specialist Akers Biosciences. In January, the firm floated on the Nasdaq Capital Market, raising $15m and, in March, it appointed co-founder Raymond Akers CEO, replacing Thomas Nicolette who had headed up the company since 2008.